Swiss drug maker Novartis AG announced Friday that it agreed to acquire all remaining rights to auto-immune drug Ofatumumab from GlaxoSmithKline Plc. The consideration payable by Novartis Pharma to GSK may reach up to $1.034 billion. Novartis has previously acquired the rights to Ofatumumab for oncology.